Skip Navigation


Public Health Ethics Advance Access originally published online on May 8, 2008
Public Health Ethics 2008 1(2):124-133; doi:10.1093/phe/phn016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1/2/124    most recent
phn016v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hollis, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hollis, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The Author 2008. Published by Oxford University Press. Available online at www.phe.oxfordjournals.org

The Health Impact Fund: A Useful Supplement to the Patent System?

Aidan Hollis*

University of Calgary

* Corresponding author: Department of Economics, University of Calgary, 2500 University Dr NW, Calgary AB, T2N 1N4, Canada. Tel.: +1403220 5861; Fax: +1403220 5861; Email: ahollis{at}ucalgary.ca.


  Abstract

The Health Impact Fund has been proposed as an optional, comprehensive advance market commitment system offering financial payments or ‘prizes’ to patentees of new drugs, which are sold globally at an administered low price. The Fund is designed to offer payments based on the therapeutic impact of the drugs or vaccines, so that innovators will have efficient incentives to develop drugs that maximize health gains. Consumers would have improved access to such drugs because of low prices.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Public Health EthicsHome page
J. Sonderholm
A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs
Public Health Ethics, July 3, 2009; (2009) php017v1.
[Abstract] [Full Text] [PDF]

Home page
 J Law Med EthicsHome page
S. Flynn, A. Hollis, and M. Palmedo
An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries
J. Law Med. Ethics, June 1, 2009; 37(2): 184 - 208.
[PDF]

Home page
 Public Health EthicsHome page
T. Pogge
Access to Medicines
Public Health Ethics, July 1, 2008; 1(2): 73 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Public Health EthicsHome page
S. W. Jarrett
Challenges to the Successful Introduction of Biotechnologies in Developing Countries
Public Health Ethics, July 1, 2008; 1(2): 104 - 109.
[Full Text] [PDF]

Home page
 Public Health EthicsHome page
M. Ravvin
Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions
Public Health Ethics, July 1, 2008; 1(2): 110 - 123.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.